Xvivo Perfusion AB (FRA:3XV)
€ 39.75 -0.3 (-0.75%) Market Cap: 1.24 Bil Enterprise Value: 1.20 Bil PE Ratio: 70.74 PB Ratio: 7.04 GF Score: 85/100

Half Year 2019 Xvivo Perfusion AB Earnings Call Transcript

Jul 12, 2019 / 12:00PM GMT
Operator

Ladies and gentlemen, welcome to XVIVO Perfusion Report Webcast. I'll now hand over to Magnus Nilsson, CEO. Please go ahead.

Magnus Nilsson;publ;CEO;MD
Xvivo Perfusion AB

()-&

Thank you, and welcome to this interim report January to June 2019. My name is Magnus Nilsson, CEO, and on my side here I have Christoffer Rosenblad, the CFO as well.

So let's start on Page #2, please. So the highlights this year -- this half year, I should say, the last quarter has been -- a lot of things happening, positive things happening. We have got the PMA, which was the full day XPS and STEEN Solution in the United States. We got patents approved for the heart preservation solution, both in the U.S. and Europe. We have had -- we can see or note positive results from the clinical safety study with the hearts device at Lund University Hospital with 6 patients with good results presented at the International Society for Heart and Lung Transplantation. We got approval from the Swedish MPA to start a clinical study for heart

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot